Bristol-Myers Squibb, Otsuka say FDA OKs Abilify for Treatment of
Irritability Associated with Autistic Disorder in Children
From M2 Europharma - Nov 23, 2009
US pharmaceutical and nutritional products maker Bristol-Myers Squibb
Company and Japanese Otsuka Pharmaceutical Co Ltd said on 20 November
that the FDA has approved the supplemental NDA for Abilify for the
treatment of irritability associated with autistic disorder in
pediatric patients ages 6 to 17 years.
www.peoplewho.org